Skip to main content

previous disabled Page of 2
and
  1. No Access

    Article

    Dating of anatase-forming diagenetic reactions in Rotliegend sandstones of the North German Basin

    Diagenetic conditions controlling authigenic formation of anatase and in situ LA-ICP-MS U–Pb isotope dating of this phase are studied in Upper Rotliegend II sandstones from two wells in NW-Germany. Anatase gre...

    S. Sindern, V. Havenith, A. Gerdes, F. M. Meyer in International Journal of Earth Sciences (2019)

  2. No Access

    Article

    Pneumologen-Barometer 2017

    Erstmalig wurde mittels Online-Befragung eine Selbsteinschätzung von ambulant in Praxen und stationär in Kliniken tätigen Pneumologen zu Therapieoptionen und ihrer Umsetzbarkeit, zur Verordnungssituation, dem ...

    Dr. T. Hering, A. Hellmann, A. Bayer in Der Pneumologe (2017)

  3. Article

    Open Access

    Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

    The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stop** therapy) following frontline nilotinib tre...

    A Hochhaus, T Masszi, F J Giles, J P Radich, D M Ross, M T Gómez Casares in Leukemia (2017)

  4. No Access

    Article

    Positionspapier zum Telemonitoring bei schlafbezogenen Atmungsstörungen

    Der Einsatz des Telemonitorings bei schlafbezogenen Atmungsstörungen (SBAS) kann zukünftig die Betreuung der Patienten wesentlich unterstützen. Ziel ist es dabei, den Ärzten zu ermöglichen, Therapieprobleme ze...

    Prof. Dr. med. W. Randerath, M. Bögel, C. Franke, A. Hellmann, B. Jany in Somnologie (2017)

  5. No Access

    Article

    Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

    The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1+ chronic myeloid leukemia (C...

    V S Hoffmann, M Baccarani, J Hasford, F Castagnetti, F Di Raimondo, L F Casado in Leukemia (2017)

  6. Article

    Open Access

    Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

    Tyrosine kinase inhibitors represent today’s treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective ra...

    A Gratwohl, M Pfirrmann, A Zander, N Kröger, D Beelen, J Novotny, C Nerl in Leukemia (2016)

  7. Article

    Open Access

    Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

    The Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study included 1089 patients with newly diagnosed chronic myeloid leukemia in chronic phase. The rate of deep ...

    A Hochhaus, G Rosti, N C P Cross, J L Steegmann, P le Coutre, G Ossenkoppele in Leukemia (2016)

  8. No Access

    Article

    The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

    This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia po...

    V S Hoffmann, M Baccarani, J Hasford, D Lindoerfer, S Burgstaller, D Sertic in Leukemia (2015)

  9. No Access

    Article

    Aus der Versorgungsforschung des Bundesverbandes der Pneumologen – WINPNEU

    Patienten mit Asthma und COPD stellen den wesentlichen Anteil einer pneumologischen Praxis dar und stehen im Mittelpunkt des alltäglichen Versorgungsauftrags der Pneumologen. Die vorliegende Untersuchung hat d...

    Prof. Dr. W. Petro, J. Andres, A. Hellmann, T. Hering, M. Weber in Der Pneumologe (2015)

  10. Article

    Open Access

    Leukemia and risk of recurrent Escherichia coli bacteremia: genoty** implicates E. coli translocation from the colon to the bloodstream

    In patients with leukemia, the portal(s) and reasons for the persistence of an Escherichia coli recurrent bacteremia remain unclear. Adult Hematology Clinic (AHC) databases at the State Clinical Hospital in Gdańs...

    A. Samet, A. Śledzińska, B. Krawczyk in European Journal of Clinical Microbiology … (2013)

  11. No Access

    Article

    The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

    The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) has revolutionized the outcome, but the prognosis of the disease i...

    V S Hoffmann, M Baccarani, D Lindoerfer, F Castagnetti, A Turkina, A Zaritsky in Leukemia (2013)

  12. No Access

    Article

    Hydrothermal gold mineralization at the Hira Buddini gold mine, India: constraints on fluid evolution and fluid sources from boron isotopic compositions of tourmaline

    We determined the boron isotope and chemical compositions of tourmaline from the Hira Buddini gold deposit within the Archean Hutti-Maski greenstone belt in southern India to investigate the evolution of the h...

    M. -S. Krienitz, R. B. Trumbull, A. Hellmann, J. Kolb, F. M. Meyer in Mineralium Deposita (2008)

  13. No Access

    Article

    Prevention of hepatitis B virus transmission from an infected stem cell donor

    A Piekarska, J M Zaucha, A Hellmann, G B McDonald in Bone Marrow Transplantation (2007)

  14. No Access

    Article

    Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript

    K Halaburda, W Prejzner, D Szatkowski, J Limon, A Hellmann in Bone Marrow Transplantation (2006)

  15. No Access

    Article

    A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group

    Purine nucleoside analogues, cladribine (2-chlorodeoxyadenosine, 2-CdA) and fludarabine (FAMP) are active agents in acute myeloid leukemias (AMLs). Synergistic interaction between FAMP or 2-CdA with cytarabine...

    A. Wrzesień-Kuś, T. Robak, A. Wierzbowska, E. Lech-Marańda in Annals of Hematology (2005)

  16. No Access

    Article

    Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

    It is unknown whether imatinib prior to myeloablative haematopoietic stem cell transplantation (HSCT) increases transplant-related toxicity. Among the side effects induced by imatinib, myelosuppression and liv...

    J M Zaucha, W Prejzner, S Giebel, T A Gooley, D Szatkowski in Bone Marrow Transplantation (2005)

  17. No Access

    Article

    Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease

    Achievement of complete donor hematopoietic chimerism (CC) is the goal of allogeneic stem cell transplantation (allo-SCT). Persistence of recipient hematopoiesis augments the risk of relapse, which is one of t...

    J Balon, K Hałaburda, M Bieniaszewska, M Reichert in Bone Marrow Transplantation (2005)

  18. Article

    Open Access

    An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma

    The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM) patients who have a long-term response to thalidomide...

    I Hus, A Dmoszynska, J Manko, M Hus, D Jawniak in British Journal of Cancer (2004)

  19. No Access

    Article

    Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy

    Our previously published study showed promising results of autologous stem cell transplantation (ASCT) in patients with primary resistant Hodgkin's disease (HD). Probabilities of overall survival (OS) and prog...

    J Czyz, R Szydlo, W Knopinska-Posluszny, A Hellmann in Bone Marrow Transplantation (2004)

  20. No Access

    Article

    Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

    To assess the efficacy of an original DAC-7 regimen: daunorubicine (DNR) 60 mg/m2/day, days 1–3; cytarabine (AraC) 200 mg/m2/day, days 1–7; cladribine (2-CdA) 5 mg/m2/day, days 1–5, 400 untreated adult acute myel...

    J Holowiecki, S Grosicki, T Robak, S Kyrcz-Krzemien, S Giebel, A Hellmann in Leukemia (2004)

previous disabled Page of 2